Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

Envoy Medical (COCH) EBIAT (2022 - 2025)

Envoy Medical's EBIAT history spans 4 years, with the latest figure at -$6.6 million for Q4 2025.

  • Quarterly results put EBIAT at -$6.6 million for Q4 2025, down 42.62% from a year ago — trailing twelve months through Dec 2025 was -$23.8 million (down 14.24% YoY), and the annual figure for FY2025 was -$23.8 million, down 14.24%.
  • EBIAT for Q4 2025 was -$6.6 million at Envoy Medical, down from -$6.5 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $1.6 million in Q3 2023 to a low of -$13.3 million in Q2 2023.
  • The 4-year median for EBIAT is -$5.3 million (2025), against an average of -$5.6 million.
  • Peak annual rise in EBIAT hit 216.73% in 2023, while the deepest fall reached 979.05% in 2023.
  • Year by year, EBIAT stood at -$11.5 million in 2022, then skyrocketed by 57.35% to -$4.9 million in 2023, then increased by 5.66% to -$4.6 million in 2024, then tumbled by 42.62% to -$6.6 million in 2025.
  • According to Business Quant data, EBIAT over the past three periods came in at -$6.6 million, -$6.5 million, and -$5.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.